Leptomeningeal metastatic disease (LMD) represents a devastating complication of non-small-cell lung cancer (NSCLC) with a poor prognosis. Our understanding of LMD is limited in the era of molecular testing and emerging therapeutic options for lung cancer.
The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study☆
Annals of Oncology | | M.M. Zheng, Y. Xia, K. Pan, F. Sun, A.C. Tan, X.R. Dong, H.Y. Tu, L.B. Tang, Y.S. Li, K. Yin, M. Borgeaud, S. Singhal, E. Zhu, J. Zhang, M. Nilsson, J. Wu, D.L. Gibbons, H. Wakelee, J.W. Neal, J. Lee, A.A. Vaporciyan, W. Ringsurongkawong, H.T. Tran, R.Z. Zhang, T. Zhang, Q. Zhou, W.Z. Zhong, W. Li, Y.C. Zhang, J.W. Riess, A. Addeo, J.V. Heymach, N. Myall, D. Tan, Y.L. Wu, X. Le
Topics: lung-cancer, skin-cancer, blood-cancer, research